Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is the leading cause of dementia worldwide, and its pathological changes often occur several years before the onset of clinical symptoms. Therefore, early identification of individuals with high risk of progression has important clinical significance for subsequent timely intervention and disease management. However, the cumulative predictive value of a single biomarker and the combined use of multiple indicators under different modeling conditions and risk scenarios is still insufficiently quantified. In this study, a Monte Carlo simulation framework was constructed based on the ADEMP (Aims,Data-generating mechanism, Estimand, Methods, Performance measures) structure to systematically evaluate the incremental contribution of four plasma biomarkers (GFAP, pTau181, pTau217 and Aβ42 / 40) to AD risk prediction. We generated survival data covering a variety of scenarios, including demographic variables, cognitive assessment scores, and biomarker measurements. The Cox proportional hazards model was used in the analysis. The basic model was compared with the extended enhanced model with biomarkers, and the predictive performance was evaluated by C index, ΔC index, ΔR2, IDI, risk stratification analysis and sensitivity test. The results showed that GFAP and pTau217 were the most prominent in independent prediction, and the improvement of prediction effect was the most significant when the four markers were combined. This incremental effect remains stable under different sample sizes and censoring rates, indicating that the conclusion has strong robustness. The above findings provide strong support for integrating plasma biomarkers into traditional AD prediction models, and also build a reference methodological framework for future preclinical evaluation of the value of new biomarkers. There are some limitations in this study. It uses simulated data rather than real clinical cases, which cannot fully reflect the heterogeneity and complexity of patient data in the real world. Future research should conduct external validation of the above results, and further explore more flexible models such as adaptive ensemble estimation, in order to ultimately achieve truly personalized AD risk assessment.
No takes yet. Share an insight, caveat, or question.
Pang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: